Miami (October 2, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at the European Respiratory ...

The latest findings on the chronic, inflammatory lung condition focus on the association of Chronic Rhinosinusitis and ...

Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...

Bronchiectasis is a long-term health condition in which airways are constantly irritated or inflamed, leading to permanent airway damage and a buildup of mucus. This often causes a chronic cough and ...

A study led by the Research Institute of the McGill University Health Center (The Institute) has identified a rare genetic variant in the ODAD4 gene that causes primary ciliary dyskinesia (PCD), a ...

In the final clip, James D. Chalmers, MBChB, PhD, notes that while the FDA approval of brensocatib is a milestone, questions remain on optimal patient selection, long-term benefits, and further ...

The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...